

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Attorney Docket No. 018733/0884

#4  
11/10/99  
RECEIVED

NOV 5 1999


TECH CENTER 1600/2900

In re patent application of

Hans J. Hansen *et al.*

Serial No. 09/337,756

Filed: June 22, 1999



Group Art Unit: 1643

Examiner: Unassigned

For: USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS  
AND THERAPY

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. § 1.56. Copies of the listed documents are submitted to comply with the provisions of 37 C.F.R. § 1.97 and 1.98.

The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Serial No. 09/337,756

TIMING OF THE DISCLOSURE


The instant Information Disclosure Statement is being submitted before the mailing of the first Office Action on the merits in compliance with 37 C.F.R. § 1.97(b).

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with M.P.E.P. § 609.

Respectfully submitted,

November 4, 1999

Date



Bernhard D. Saxe

Reg. No. 28,665

FOLEY & LARDNER  
Suite 500  
3000 K Street, N.W.  
Washington, DC 20007-5109  
(202) 672-5300